CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $581.85M, above the global median of $548.88M
- PositionReturn on equity is 25.7%, higher than 95% of its Medical Devices peers (median 2.5%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
943.29MUSDvs all stocks (USD)
Trailing P/E
17.33xvs Medical Devices peers
Revenue (TTM)
581.85MUSDvs all stocks (USD)
Profit Margin
9.36%vs Medical Devices peers
Beta
0.6510xvs all stocks
52-Week Change
108.61%vs all stocks
Market Capitalization
943.29MUSDvs all stocks (USD)
Enterprise Value
1.21BUSDvs all stocks (USD)
Trailing P/E
17.33xvs Medical Devices peers
Forward P/E
14.70xvs Medical Devices peers
PEG Ratio
0.0502xvs Medical Devices peers
Price to Sales (TTM)
1.59xvs Medical Devices peers
Price to Book (MRQ)
4.04xvs Medical Devices peers
Enterprise to Revenue
2.07xvs Medical Devices peers
Enterprise to EBITDA
15.05xvs Medical Devices peers
Gross Margin
68.97%vs Medical Devices peers
Profit Margin
9.36%vs Medical Devices peers
Operating Margin
12.23%vs Medical Devices peers
Return on Assets (TTM)
5.49%vs Medical Devices peers
Return on Equity (TTM)
25.68%vs Medical Devices peers
Revenue (TTM)
581.85MUSDvs all stocks (USD)
Revenue per Share (TTM)
8.65USDUpdated Sep 27, 2026Quarterly Revenue Growth
3.80%vs Medical Devices peers
Gross Profit (TTM)
399.45MUSDvs all stocks (USD)
EBITDA (TTM)
106.36MUSDvs all stocks (USD)
Net Income (TTM)
54.46MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
348.30%vs Medical Devices peers
Operating Cash Flow (TTM)
96.87MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
67.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
44.34MUSDFY2025 · Dec 31, 2025Revenue
568.09MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
179.93MUSDFY2025 · Dec 31, 2025Gross Profit
388.16MUSDFY2025 · Dec 31, 2025Operating Income
56.29MUSDvs all stocks (USD)
Pre-tax Income
25.71MUSDFY2025 · Dec 31, 2025Income Tax Expense
-1.56MUSDFY2025 · Dec 31, 2025Net Income
27.27MUSDFY2025 · Dec 31, 2025EBIT
52.20MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
101.85MUSDFY2025 · Dec 31, 2025Research & Development
12.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
314.03MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
26.49MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
27.27MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-4.54MUSDFY2025 · Dec 31, 2025Operating Cash Flow
93.18MUSDFY2025 · Dec 31, 2025Free Cash Flow
90.62MUSDDerived from operating cash flow minus capital expenditure. This filing charges 47.01M of depreciation against 2.56M of capital expenditure, and its own free-cash-flow line reads 72.11M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
51.24MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
27.27MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
47.01MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-909.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.67MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.16MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-916.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.89MUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.56MUSDFY2025 · Dec 31, 2025Net Acquisitions
-686.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.25MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
76.91MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-119.82MUSDFY2025 · Dec 31, 2025Other Financing Charges
-21.30MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-62.14MUSDFY2025 · Dec 31, 2025Shares Outstanding
68.21MSharesUpdated Sep 27, 2026Float Shares
34.30MSharesUpdated Sep 27, 2026Shares Short
2.93MSharesUpdated Sep 27, 2026Short Ratio
5.37daysvs all stocks
Short % of Shares Outstanding
6.25%vs all stocks
% Held by Insiders
11.65%vs all stocks
% Held by Institutions
83.08%vs all stocks
Total Cash (MRQ)
30.39MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4450USDUpdated Sep 27, 2026Total Debt (MRQ)
263.75MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.9507xvs Medical Devices peers
Current Ratio (MRQ)
1.69xvs Medical Devices peers
Book Value per Share (MRQ)
3.35USDUpdated Sep 27, 2026Total Assets
683.56MUSDvs all stocks (USD)
Total Current Assets
272.84MUSDFY2025 · Dec 31, 2025Total Liabilities
455.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
410.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
294.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
160.38MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
51.24MUSDFY2025 · Dec 31, 2025Accounts Receivable
128.30MUSDFY2025 · Dec 31, 2025Inventory
82.24MUSDFY2025 · Dec 31, 2025Accounts Payable
10.93MUSDFY2025 · Dec 31, 2025Short-term Debt
15.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
21.06MUSDFY2025 · Dec 31, 2025Long-term Debt
278.95MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
15.35MUSDFY2025 · Dec 31, 2025Common Stock (Book)
83.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-334.93MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
228.45MUSDvs all stocks (USD)
52-Week Low
6.37USDUpdated Sep 27, 202652-Week High
15.89USDUpdated Sep 27, 202652-Week Change
108.61%vs all stocks
Beta
0.6510xvs all stocks
50-Day MA
13.44USDUpdated Sep 27, 2026200-Day MA
10.09USDUpdated Sep 27, 2026Avg 10-Day Volume
457.17KSharesUpdated Sep 27, 2026Avg 30-Day Volume
530.73KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
0.7800USDUpdated Sep 27, 2026Other Income / Expense
-4.10MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 25.7%, higher than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: 0.26Industry median: 0.03Industry P95: 0.17Peers compared: 102
Financial Health
Altman Z-Score 1.84: grey zoneSignificant
Altman Z-Score: 1.84
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $581.85M, above the global median of $548.88MNotable
Revenue (USD): 581,848,000Global Median: 548,883,780.48
Levered free cash flow is $67.76M, above the global median of $18.73MNotable
Levered free cash flow (USD): 67,764,128Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
KPC Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharma Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cullinan Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Medincell SA
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Harmony Biosciences Holdings, Inc.
3 interpretationsFCF Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Rigel Pharmaceuticals, Inc.
3 interpretationsFCF Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated
Trane Technologies plc
3 interpretationsFCF Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin Elevated